Clinical Trials Logo

Filter by:
NCT ID: NCT02639988 Suspended - Type 2 Diabetes Clinical Trials

Impact of Rheumatoid Arthritis on the Course of Type 2 Diabetes During a Longitudinal Follow-up of 5 Years

INSPIRED
Start date: April 13, 2016
Phase:
Study type: Observational

The purpose of this study is to determine whether patients with rheumatoid arthritis and type 2 diabetes experience a more severe disease course compared to control patients with osteoarthritis and type 2 diabetes

NCT ID: NCT02742883 Suspended - Clinical trials for Diffuse, Intrinsic Pontine Glioma

A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)

Start date: April 13, 2016
Phase: Phase 2
Study type: Interventional

Current therapies for diffuse, intrinsic pontine glioma (DIPG) provide very limited benefit to the patient. The rationale for the use of Antineoplaston therapy in this protocol study derives from experience with subjects from prior Phase 2 studies and Compassionate Exemption patients treated with Antineoplaston therapy at the Burzynski Clinic. This study is designed to analyze the efficacy and safety of Antineoplaston therapy in five separate DIPG patient cohorts, which are defined by age and prior therapy. This is a two stage study with 20 patients in each cohort being enrolled in the first stage and an additional 20 patients being enrolled in the second stage, if pre-determined efficacy endpoints in the first stage are realized.

NCT ID: NCT03188393 Suspended - Clinical trials for Stage IIIA Breast Cancer

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

Start date: April 13, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same.

NCT ID: NCT04498585 Suspended - Clinical trials for Cognitive Impairment

Virtual Reality to Reduce Delirium

Start date: April 14, 2021
Phase: N/A
Study type: Interventional

Delirium has been long considered as a major contributor to cognitive impairments following a critical illness. Currently, both pharmacologic and non-pharmacologic prevention and treatment strategies are used in the intensive care unit, despite these strategies remaining controversial. However, with previous studies showing the feasibility of using virtual reality (VR) within the critical care setting, the investigators propose to use this technology to investigate the effect of 360-degree immersive virtual reality stimulation on the incidence of delirium in the ICU. Stimulation will be provided for 30 minutes, three times a day, evenly spaced between 7:00 AM and 7:00 PM, using a commercially available head-mounted display. The investigators hypothesize that by providing relaxing virtual environments to patients through a head-mounted display and headphones, the incidence of delirium will be lower compared to the control group receiving no VR stimulation. Secondary outcomes will include evaluating the movement patterns and intensity between the intervention and control group, and between patients with and without delirium, using inertial measurement units and an under mattress bed sensor. It is hypothesized that it will be possible to detect difference in movement patterns between groups and identify patterns indicating the presence or absence of delirium. Secondary objective also include the evaluation of the effect of VR on duration of delirium. Here it is hypothesized that the duration of delirium will be shorter in participants receiving the VR stimulation compared to those in the control group. Physiological parameters (e.g. heart rate, respiration rate, oxygen saturation, etc.) will also be recorded during the stimulation to further understand what, if any, effect VR has.

NCT ID: NCT05262699 Suspended - Stroke Clinical Trials

Crossmodal Learning in Therapeutic Processes (Task 2-1)

Start date: April 14, 2021
Phase: N/A
Study type: Interventional

Interventional study of the effects of vibro-tactile feedback on behavioral deficits and learning during motor training in patients with stroke.

NCT ID: NCT03462979 Suspended - Quality of Life Clinical Trials

Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease

Start date: April 15, 2018
Phase: N/A
Study type: Interventional

This study aims to investigate how knowledge of gluten immunogenic peptide (GIP) levels in stool and urine affects subsequent adherence to a gluten-free diet. Half of the participants will receive results in real-time using a home device and the other half will store samples to be tested at the end of the 30 week study. Participants will also have a diet review with a dietitian at the beginning of the end of their study and be asked questions about their symptoms, gluten-free diet adherence and quality of life.

NCT ID: NCT03905772 Suspended - Clinical trials for Electrical Stimulation

Neuromuscular Adaptations After Training in the Muscle Belly of Triceps Surae

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

This study aims to evaluate on an acute session of the central and peripheral contributions of electrical stimulation on the muscle belly of the triceps surae, electrical stimulation of the tibial nerve and voluntary exercise of the triceps surae muscle, and identify responders individuals and non-responders to stimulation of the tibial nerve. Another objective of the study is to compare the effects of conventional electrical stimulation applied to the sciatic triceps muscle, tibial nerve stimulation and voluntary exercise after eight weeks of training in healthy individuals.

NCT ID: NCT04470999 Suspended - Covid19 Clinical Trials

Changes in Cellular Immune Profile During COVID-19 Infection

Start date: April 15, 2020
Phase: N/A
Study type: Interventional

Clinical specimens are collected from individuals either recovered from or with active SARS-CoV-2 infection to support process and analytical development for a potential cell-based immunotherapy in preclinical research, SRPH-CVD-01. SRPH-CVD-01 is an allogeneic cell-based immunotherapy candidate to be investigated in a subsequent clinical trial under a future FDA IND to treat people suffering from COVID-19. Enrolled participants provide a venous blood specimen (up to 40mL) to be used in preclinical studies and research and development of SRPH-CVD-01. Subjects may eventually be asked to undergo leukapheresis for peripheral blood mononuclear cell (PBMC) collection and their specimens will be used to further develop the SRPH-CVD-01 cell product, including a cGMP compliant process to be applied under the future FDA IND.

NCT ID: NCT05212727 Suspended - Clinical trials for Neurological Disorders

Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders

Start date: April 15, 2022
Phase:
Study type: Observational

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by neurological disorders and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of neurological disorders and associated cognitive changes.

NCT ID: NCT05414747 Suspended - Retinal Detachment Clinical Trials

Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)